% | $
Quotes you view appear here for quick access.

VIVUS Inc. Message Board

  • rstos14 rstos14 Feb 20, 2013 8:57 PM Flag

    Why Belviq will only be a catalyst to Qsymia Sales.

    We'll start out with the obvious.. increased awareness in the obesity market and both companies driving to get additional insurance coverage will facilitate Qsymia sales. The real aspect that will be the catalyst that drives Qsymia Sales is efficacy. Belviq provided approx a placebo adjusted weight loss of 3% in comparison to Qsymia's nearly 10% placebo adjust efficacy. Another aspect that will be helpful to qsymia sales is the immense drop out rate belviq saw in clincial trials 50-60% when the drug was provided for free. Imagine the drop out rate when cash is king and less than 30% of patients are covered, especially given the rumors on the arena board of 200+/mo. script costs. Dropout leads to patients seeking alternatives. Qsymia is less than two months away from a decision on REMs for retail access which will further facilitate steady script growth. Belviq's marginal efficacy and drop out rate plus increased obesity awareness will only help drive Qsymia sales in my opinion.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.31-0.01(-0.43%)Jul 2 4:00 PMEDT